Wire · opportunities
Givinostat Shows Extended Ambulation in DMD Patients, MRI Data Released
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 8 July 2026 · Fusion42 review
Givinostat, an oral HDAC inhibitor approved for DMD in 2024, shows extended ambulation (median age 17.3 years vs. 11.0–13.4 year benchmark) and quantitative MRI evidence of reduced muscle fat infiltration in Phase 3 extension data presented at ICNMD 2026. The mutation-agnostic mechanism and durable safety profile position it as a platform therapy ahead of Health Canada regulatory decision.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
Quantitative MRI biomarkers validate HDAC inhibition as disease-modifying mechanism in DMD; mutation-agnostic profile and durable safety enable broader patient access and long-term commercial runway—critical for founders building next-gen DMD therapies or imaging diagnostics.
◆ Coverage
1 source · 8 Jul 2026
◆ Related on Wire
◆ Topics